Search
  • Beth Lawrence

Interview with Marek Jasinski, Founder and CEO, 100THX


On June 12, 2019, Marek Jasinski, Founder and CEO of 100THX, will be speaking at Kahner Global's 4th Annual Cannabis Private Investment Summit Toronto. The event will host more than 150 industry leaders and investors for a day of collaboration and networking.

1. Marek, tell us a little bit about your background.

I am a self-taught entrepreneur who started in the 90's. I began in the technology sector, I taught myself how to program Assembly, C and about 40 other programming languages. Before graduating from highschool in the mid 90's, I created technology which allowed full internet service to customers. The company grew from just four phone lines to over 300 in just ten months, we were the first in Toronto/North America to do so using MajorBBS. I created various successful startups in the technology sector, after which I begun exploring particle physics, quantum mechanics, and other scientific fields. I focused on biology in 2000 and landed on genetics in 2003. After realizing what genetic code is in 2003, I pointed out it is a mathematical impossibility for there to be "Junk DNA" of that size, a term that was used at the time describing genes that were thought to be of no consequence on our life. As an Artificial Intelligence programmer learning the genetic code was an amazing experience. Today, I strive to program and decipher the ultimate AI programming language in the universe, the genetic code.

2. When did you enter the cannabis industry, and what was the driving force behind it?

I entered the Cannabis space around 2012, at the time I used AI programs to derive biological actions. Output of these programs pointed out that my medical condition would benefit from compounds found in Cannabis. I met Dr. Sam Mellace when I sought an experienced help. Dr. Sam showed me his operation in B.C. and taught me all about Cannabis. I continued to apply AI to Cannabis, probing for biological actions inside cells without cultured cells. This research led me to very interesting insights into Cannabis, like the impact on CD4/CD34 cells which predicted human negative impact of Cannabis on certain specific viruses.

3. How did 100THX come to be, and what is the meaning behind the name?

When my mentor and longtime friend Edward Palonek passed away, I reconnected with my now partners whom I worked with for Edward's company FoundMoney. 100 signifies the purity of compounds, no pesticides and Non-GMO, something that should become a standard requirement for medical treatments. THX encompasses all the known and the many unknown botanical compounds.

4. If you can, explain a bit about how you combine traditional scientific disciplines with artificial intelligence.

Today it is difficult to obtain consistent results when it comes to invitro and invivo testing. My experience in AI combined with various fields of science allowed me to exploit biological reaction using a computer. In order to accomplish this, I have devised a new method of DNA understanding and its interactions with messenger molecules, peptides, amino acids and proteins. With more than 37 billion cells, it is near impossible for any human to precisely analyze actions within a single cell. In a way I created a new language to decipher DNA instructions on those calculations inside the cells.

5. Why is this method unique, and what unique results does it produce?

Our unique methods tie the various genetic expression across the human body, from saliva to blood. We are further able to separate the cells to specific genetic expressions, allowing the AI software to analyze and determine what specific compounds will work and which ones will not. Moreover, we are able to discern at genetic level the amount of medications a person requires. We are able to test genetic expressions for damages to the genomic code, something no human is able to do today. Our epigenetic technology is superior to anything currently on the market, and will likely lead to new rapid DNA testing technologies.

6. Your team includes executives from various industries and concentrations, including medicine, science and hospitality. Is this by design?

Yes, they all bring in unique abilities, adding collectively their strengths and experience. Having known them for a long time in both personal and professional capacity. Having an unique ability to utilize human capacity in various roles set the stage to excel our growth.

7. Please describe the Enoch Project, and its significance to growers and the industry as a whole.

This project is an indirect offshoot from the therapy I created to "treat/cure" supraventricular tachycardia. I saw how easy it is to exploit the genetic code, in this case it was to activate and promote progenitor cells among many other to repair heart circuitry. Prior to that, I was able to make plants express very specific genetic code, I combined the two technologies and Enoch was born. Enoch is a NON-GMO, non CRISPR, non virus, method of genetic activation. We all have genetic code that is activated by the body when needed, i.e. to produce a certain antibody, Enoch is a very clever way to accomplish the same on the genetic code. There are no outside genes and the result is a faster stronger growth of the plant. Another interesting observation I have made using this technology is that the fertilizers in use today lack and block the basic functions of plants, these functions include carbon flow, excretion, protein formations, and many others. Enoch will likely become defacto standard of growing agricultural crops.

8. Your AI-GTS product is set to begin trial runs in May. What makes this the “Future of Medicine?”

This service is unlike any other in the industry, it is innovative in multiple ways. We found a way to extract genetic material from specific cells in the body. We utilize the latest in AI processing to derive meaningful data from blood and saliva. This allows us to target specific diseases and treatments with very high level of precision. We see this technology utilized across the globe, from medical clinics to hospitals. Due to the use of A.I. we no longer require doctors to undergo significant training as the AI will interpret the data for the doctors. Based on this, doctors are able to spend less time on analysis and focus on the patient. By comparison to the 2000 computer boom, A.I.-GTS is like the backbone servers that process and interpret data.

9. What health conditions have you utilized your technology for thus far?

I have used it for Supraventricular tachycardia (SVT), 3-BP cancer treatment, Adiposis Dolorosa and Tourette's Syndrome. I'm currently working on calculating an effective treatment plan for advanced Alzheimer's with a very specific genetic expression. We aim to have this treatment approved for a selected few patients within the next few months.

10. Your Feed formula is said to be ‘better than organic.’ Please describe the key differentiators between your product and other similar products on the market.

Today's formulas require Nitrogen and other key chemical compounds that plants normally have pulled from the soil and air. Our formula does not contain any lab-created chemical. Instead, it promotes the plant to seek chemicals like Nitrogen from soil and air. The formula provides the necessary basic nutrients for the plant to do so and the plants that cannot accomplish this on their own, are considered unhealthy and thus eliminated. While this may seem like Darwinism, it is not, it’s a method of promoting growth of healthy plants.

11. What’s next for artificial intelligence in the cannabis industry and beyond?

We strive to help the industry through our unique perspective. While anecdotal web user data may prove useful for marketing purposes, we expect the medical community to embrace the use of genetic AI testing. Personalized treatments are now possible due to technological advancements, and providing significant savings to healthcare providers.

12. What’s next for 100THX?

Our focus is on the genetic testing service. However, we are running trials of our feed formulas and other technological advancements. We are very fortunate to have such a wonderful management team.

Our main focus is to lunch on AI-GTS while remaining projects are being evaluated for sale. We utilize AI to cut down on R&D, sales and marketing. Our AI adds to our collective goals by offering information that would normally take years to discover. We continue to adapt to change quickly, both on the technological side and business marketplace.

To follow 100THX, visit:

http://www.100thx.ca

The Cannabis Private Investment Summit showcases the best and brightest cannabis entrepreneurs in the industry and is the premiere summit for institutional investors, family offices, and ultra high net worth investors. To request an invitation to Kahner Global’s 4th Annual Cannabis Private Investment Summit Toronto, being held on June 12, 2019, click here.

#100THX #MarekJasinski #Toronto

196 views

© 2020 by Kahner Global